Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Fuso: Operating Profits Down 56.6%
November 23, 2009
- Univ. Hospitals Should Use More Generics: Mr Isobe
November 23, 2009
- Banyu to Boost Its Vaccine Business with Pneumovax, Gardasil
November 16, 2009
- InCROM to Conduct Mock PI Trials for Drug Makers’Employees
November 16, 2009
- GSK to Promote Cervarix Targeting All Dept. and Deploying over 1,000 MRs
November 16, 2009
- Hospira Japan Launches GemStar PCA Pump
November 16, 2009
- Medipal to Further Drug Distribution System Reform
November 16, 2009
- Quintiles Is More Than a CRO: Dr Winstanly
November 16, 2009
- Alfresa to Begin Business in China in Earnest
November 16, 2009
- Eisai Reshuffles R&D System to Speed Up Development of Anticancer Drugs
November 16, 2009
- Big Changes in Style of Discussions at Chuikyo
November 16, 2009
- Strong Yen Hit Top-Eight Domestic Companies’Performance
November 16, 2009
- Pricing Rule to Be Revised for New Products Containing Existing API: Chuikyo
November 16, 2009
- Half-Year Business Results of Domestic Companies: 2 （１）
November 16, 2009
- Share of Original Drugs Not Decreasing Much in Japan Despite Large Fall in Prices: Korosho Survey
November 16, 2009
- Half-Year Business Results of Domestic Companies: 2 （２）
November 16, 2009
- Korosho Considers Revising Medical Fees to Induce Doctors to Prescribe Fewer Antipsychotics
November 16, 2009
- Deeply Cut Prices of New Drugs to Save Failing Healthcare System: Hodanren
November 16, 2009
- REGULATORY NEWS IN BRIEF
November 16, 2009
- Takeda Ties Up with Amylin for Treatment of Obesity
November 16, 2009
ページ
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…